The effects of four sand contents on the compressive, flexural and splitting-tensile strength of cement mortars were evaluated. Moreover, we experimentally investigated the pore structure of cement mortar brought abou...The effects of four sand contents on the compressive, flexural and splitting-tensile strength of cement mortars were evaluated. Moreover, we experimentally investigated the pore structure of cement mortar brought about by changing the sand content and water/cement ratio. The changes in the pore structure were quantified by measuring the porosity and pore size distribution obtained by using mercury intrusion porosimetry（MIP） technique. The test results show that the strengths of cement mortar increase with increasing sand content. It is also suggested that the traditional water/cement ratio law can be applied to cement mortar with different sand contents, provided that a slight modification is introduced. Sand content is an important parameter influencing the pore structure of cement mortar. Moreover, there is a good relationship between the pore structure and strength of cement mortar.展开更多
Organic sulfone compounds,exhibiting interesting bioactivities,were widely applied in the field of pharmaceutical and medicine.And numerous of sulfuryl group-involved drugs were approved by the Food and Drug Administr...Organic sulfone compounds,exhibiting interesting bioactivities,were widely applied in the field of pharmaceutical and medicine.And numerous of sulfuryl group-involved drugs were approved by the Food and Drug Administration(FDA).Odevixibat,maralixibat chloride and belzutifan approved in 2021 could be applied in the treatment of progressive familial intrahepatic cholestasis(PFIC),cholestatic pruritus and clear cell renal cell carcinoma(ccRCC),respectively.In 2022,abrocitinib,pyrukynd and voquezna were approved for the treatment of atopic dermatitis,pyruvate kinase deficiency(PKD)and acid-related disorders,respectively.Defencath for preventing bloodstream infections,sparsentan for treatment of proteinuria related to IgA nephropathy,and xacduro for treatment of hospital-acquired bacterial pneumonia(HABP)were approved in 2023.In this review,the synthesis and therapies of these sulfuryl group-involved drugs approved from 2021 to 2023 are discussed in details.展开更多
基金Founded by the National Natural Science Foundation of China(Nos.51279054 and 51279052)
文摘The effects of four sand contents on the compressive, flexural and splitting-tensile strength of cement mortars were evaluated. Moreover, we experimentally investigated the pore structure of cement mortar brought about by changing the sand content and water/cement ratio. The changes in the pore structure were quantified by measuring the porosity and pore size distribution obtained by using mercury intrusion porosimetry（MIP） technique. The test results show that the strengths of cement mortar increase with increasing sand content. It is also suggested that the traditional water/cement ratio law can be applied to cement mortar with different sand contents, provided that a slight modification is introduced. Sand content is an important parameter influencing the pore structure of cement mortar. Moreover, there is a good relationship between the pore structure and strength of cement mortar.
文摘Organic sulfone compounds,exhibiting interesting bioactivities,were widely applied in the field of pharmaceutical and medicine.And numerous of sulfuryl group-involved drugs were approved by the Food and Drug Administration(FDA).Odevixibat,maralixibat chloride and belzutifan approved in 2021 could be applied in the treatment of progressive familial intrahepatic cholestasis(PFIC),cholestatic pruritus and clear cell renal cell carcinoma(ccRCC),respectively.In 2022,abrocitinib,pyrukynd and voquezna were approved for the treatment of atopic dermatitis,pyruvate kinase deficiency(PKD)and acid-related disorders,respectively.Defencath for preventing bloodstream infections,sparsentan for treatment of proteinuria related to IgA nephropathy,and xacduro for treatment of hospital-acquired bacterial pneumonia(HABP)were approved in 2023.In this review,the synthesis and therapies of these sulfuryl group-involved drugs approved from 2021 to 2023 are discussed in details.
